EBITDA Margin % is calculated as EBITDA divided by its Revenue. MeiraGTx Holdings's EBITDA for the
three
months ended in Mar. 2026 was €-35.00 Mil. MeiraGTx Holdings's Revenue for the
three
months ended in Mar. 2026 was €0.25 Mil. Therefore, MeiraGTx Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was -13,832.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MeiraGTx Holdings EBITDA Margin % Related Terms
MeiraGTx Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MeiraGTx Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:328 vs DRTS, LXRX, CGEM: EBITDA Margin % Comparison
For the Biotechnology subindustry, MeiraGTx Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MeiraGTx Holdings (FRA:328) has a EBITDA Margin % of -13,832.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MeiraGTx Holdings and its competitors. According to the industry distribution chart, MeiraGTx Holdings ranks #519 out of 945 companies in the Biotechnology industry, placing it in the top 54.9%.
Is MeiraGTx Holdings' EBITDA Margin % too high?
MeiraGTx Holdings' current EBITDA Margin % is -13,832.02%. Based on the distribution chart, MeiraGTx Holdings ranks #519 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MeiraGTx Holdings has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' EBITDA Margin % compare to DRTS and LXRX?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #519 out of 945 companies for EBITDA Margin %. This places MeiraGTx Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current EBITDA Margin % is -13,832.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €21.06, compared to a current price of €10.30 — trading 51.1% below its estimated fair value. The current EBITDA Margin % is -13,832.02%. MeiraGTx Holdings' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current EBITDA Margin % is -13,832.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €10.30 is trading 51.1% below its estimated GF Value™ of €21.06.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for FRA:328:
EBITDA Margin %: -13,832.02%
GF Value™: €21.06 vs. price of €10.30 (51.1% below fair value)
No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
51GF Score
Get the complete analysis for FRA:328
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:328 has been successfully added to your 
